Adagene Advances Second Stage Study in Collaboration with MSD

Adagene has revealed the elaboration of its second-stage study for their latest candidate, ADG126, an antibody that promotes an immune response against cancer, and Keytruda, MSD’s treatment for colorectal cancer.  

The study will expand to involve just over 50 individuals, with the promise of progressing the initial effectiveness outcomes and risk analysis.  

The research is investigating how well a blend of ADG126 works with pembrolizumab in treating MSS CRC.  

Peter Luo, the head executive at Adagene, stated, “Following the completion of enrollment of 12 additional patients at the end of last year, together with our ongoing expansion plans, we are on track to deliver data in 2024 that support the findings released at the recent ASCO-GI Symposium.”  

Luo went on to add, “We have initiated the evaluation of ADG126 20mg/kg loading doses in combination with pembrolizumab, which we believe can unlock even greater efficacy for MSS CRC in planned cohort expansion, while still maintaining a robust safety profile.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.